New score predicting for prognosis in PML-RARA+, AML1-ETO +, or CBFB-MYH11+ acute myeloid leukemia based on quantification of fusion transcripts

Blood

Volumn 102, Issue 8, 2003, Pages 2746-2755

  Schnittger, Susanne ^a   Weisser, Martin ^b   Schoch, Claudia ^b   Hiddemann, Wolfgang ^b   Haferlach, Torsten ^b   Kern, Wolfgang ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; HYBRID PROTEIN; MITOXANTRONE; PROTEIN AML1 ETO; PROTEIN CBFB MYH11; PROTEIN PML RARA; RETINOIC ACID; TIOGUANINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE DURATION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FUSION GENE; GENETIC TRANSCRIPTION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE;

EID: 0141923916     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-03-0880     Document Type: Article

References (56)

1. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-1320.
2. Mrozek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:19-47.
3. Plantier I, Lai JL, Wattel E, Bauters F, Fenaux P. Inv(16) may be one of the only 'favorable' factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up. Leuk Res. 1994;18: 885-888.
4. Larson RA, Williams SF, Le Beau MM, Bitter MA, Vardiman JW, Rowley JD. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood. 1986;68:1242-1249.
5. Martinelli G, Ottaviani E, Testoni N, et al. Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures. Bone Marrow Transplant. 1999;24:694-697.
6. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759-767.
7. Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia. 1996;10:1288-1295.
8. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999;94:1192-1200.
9. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all- trans retinoic acid: result of the Randomized MRC Trial. Blood. 1999;93:4131-4143.
10. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107:69-79.
11. Claxton DF, Liu P, Hsu HB, et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood. 1994;83:1750-1756.
12. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
13. Miyamoto T, Nagafuji K, Harada M, Niho Y. Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia. Leuk Lymphoma. 1997;25:69-75.
14. Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia. 2000;14:1362-1370.
15. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999;94:12-22.
16. Grimwade D. The significance of minimal residual disease in patients with t(15;17). Best Pract Res Clin Haematol. 2002;15:137-158.
17. Ikeda K, Sasaki K, Tasaka T, et al. PML-RAR alpha fusion transcripts by RNA PCR in acute promyelocytic leukemia in remission and its correlation with clinical outcome. Int J Hematol. 1994;60:197-205.
18. Korninger L, Knobl P, Laczika K, et al. PML-RAR alpha PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2-3 months. Br J Haematol. 1994;88:427-431.
19. Grimwade D, Howe K, Langabeer S, Burnett AK, Goldstone A, Solomon E. Minimal residual disease detection in acute promyelocytic leukemia by reverse transcriptase PCR: evaluation of PML-RARA and RARA-PML assessment in patients who ultimately relapse. Lancet. 1996;10:61-66.
20. Diverio D, Rossi V, Awisati G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood. 1998;92:784-789.
21. Marcucci G, Caligiuri MA, Bloomfield CD. Defining the "absence" of the CBFbeta/MYH 11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. Blood. 1997;90:5022-5024.
22. Tobal K, Newton J, Macheta M, et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood. 2000;95:815-819.
23. Costello R, Sainty D, Blaise D, et al. Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBF beta/MYH11-positive acute myeloblastic leukemia. Blood. 1997;89:2222-2223.
24. Tobal K, Johnson PR, Saunders MJ, Harrison CJ, Liu Yin JA. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol. 1995;91:104-108.
25. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 1993;82:712-715.
26. Jurlander J, Caligiuri MA, Ruutu T, et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood. 1996;88: 2183-2191.
27. Morschhauser F, Cayuela JM, Martini S, et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. J Clin Oncol. 2000;18:788-794.
28. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994.
29. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia. 1998;12:1482-1489.
30. Marcucci G, Caligiuri MA, Dohner H, et al. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia. 2001;15:1072-1080.
31. Mensink E, van de LA, Schattenberg A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol. 1998;102:768-774.
32. Cassinat B, Zassadowski F, Balitrand N, et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia. 2000;14:324-328.
33. Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia. 1999;13:1825-1832.
34. Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and potential. Biotechniques. 1999;26:112-115.
35. Yin JA, Tobal K, Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance. Br J Haematol. 1999;106:578-590.
36. Visani G, Buonamici S, Malagola M, et al. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study. Leukemia. 2001;15:1696-1700.
37. Hochhaus A, Weisser A, La Rosee P, et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia. 2000; 14:998-1005.
38. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95:790-794.
39. Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet. 1994; 343:196-200.
40. Krauter J, Hoellge W, Wattjes MP, et al. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes Chromosomes Cancer. 2001;30:342-348.
41. Krauter J, Wattjes MP, Nagel S, et al. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) -positive AML patients. Br J Haematol. 1999;107:80-85.
42. Buonamici S, Ottaviani E, Testoni N, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood. 2002;99:443-449.
43. Guerrasio A, Pilatrino C, De Micheli D, et al. Assessment of minimal residual disease (MRD) in CBFbetaJMYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia. 2002; 16:1176-1181.
44. Haferlach T, Bennett JM, Löffler H, et al. Acute myeloid leukemia with translocation (8;21): cytomorphology, dysplasia and prognostic factors in 41 cases. Leuk Lymphoma. 1996;23:227-234.
45. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116-4124.
46. Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol. 2003;21:256-265.
47. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AM-LCG) 1992 trial. Blood. 2003;101:64-70.
48. Buchner T, Hiddemann W, Wormann B, et al. Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary? Int J Hematol. 2000;72:285-289.
49. Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16:53-59.
50. Mahlknecht U, Schnittger S, Ottmann OG, et al. Chromosomal organization and localization of the human histone deacetylase 5 gene (HDAC5). Biochim Biophys Acta. 2000;1493:342-348.
51. Evans P, Jack A, Short M, et al. A single tube nested RT-PCR for detecting the common myeloid specific chromosomal translocations. Leukemia. 1995;9:1285-1286.
52. Weisser M, Pihusch M, Schoch C, Haferlach T, Hiddemann W, Schnittger S. Comparative analysis of housekeeping gene expression in hematologic cell populations of healthy individuals using quantitative real time RT-PCR [abstract]. Blood. 2001;98:111a.
53. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
54. Gallagher RE, Yeap BY, Bi W, et al. Quantitative real-time RT-PCR analysis of PML-RARα mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood. 2003;101:2521-2528.
55. Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 2002;99:3517-3523.
56. Pallisgaard, N, Clausen N, Schroder H, Hockland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer. 1999;26:355-365.